Moleculin Biotech (MBRX) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Quantum Biopharma is the larger company by market cap ($8.3 million vs $8.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBRX | QNTM |
|---|---|---|
| Share price | $7.74 | $1.29 |
| Market cap | $8.22M | $8.29M |
| 1-day change | -2.40% | -9.15% |
| YTD return | — | -82.33% |
| 1-year return | — | -77.60% |
| 5-year return | — | -98.51% |
| P/E ratio (TTM) | 0.04 | — |
| EPS (TTM) | $179.60 | $-3.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-33.56M | — |
| 52-week high | $202.50 | $12.42 |
| 52-week low | $3.22 | $1.26 |
| Distance from 52-week high | -96.18% | -89.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +55.04% | +851.16% |
| Average volume | 44.66K | 148.83K |
| Shares outstanding | 1.06M | 6.43M |
| Employees | 17 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
MBRX vs QNTM FAQ
Which is bigger, Moleculin Biotech or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $8.29M compared with $8.22M for Moleculin Biotech (MBRX).
Are Moleculin Biotech and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.